牙龈卟啉单胞菌在非酒精性脂肪肝病进展中的作用

doi:10.13591/j.cnki.kqyx.2024.02.014

摘要/Abstract

摘要：

以牙龈卟啉单胞菌为代表的牙周致病菌不仅危害口腔健康,还与非酒精性脂肪肝病等口腔外疾病有着重要联系。牙龈卟啉单胞菌及其产物可通过血行途径和肠道途径等多种途径促进非酒精性脂肪肝病的发展,本文就相关作用途径及可能机制作一综述。

关键词: 牙龈卟啉单胞菌, 牙周炎, 非酒精性脂肪肝病, 血行途径, 肠道途径

Abstract:

Porphyromonas gingivalis(P. gingivalis), a key pathogen of periodontitis, not only harms oral health, but also has an important relationship with the development of many extraoral diseases, such as non-alcoholic fatty liver disease. P. gingivalis and its products can promote the development of non-alcoholic fatty liver disease through hematogenous and intestinal pathways. In this paper, the pathway and possible internal mechanisms involved are briefly described.

Key words: Porphyromonas gingivalis, periodontitis, non-alcoholic fatty liver disease, hematogenous pathway, intestinal pathway

中图分类号:

R781.4

戴柯, 戴周丽, 刘荣场, 查光玉, 曹明国. 牙龈卟啉单胞菌在非酒精性脂肪肝病进展中的作用[J]. 口腔医学, 2024, 44(2): 152-155.

DAI Ke, DAI Zhouli, LIU Rongchang, ZHA Guangyu, CAO Mingguo. The role of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease[J]. Stomatology, 2024, 44(2): 152-155.

参考文献 43

[1]	Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD:A consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(1):60-78.
[2]	Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH:Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1):11-20. doi: 10.1038/nrgastro.2017.109 pmid: 28930295
[3]	Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe[J]. Hepatology, 2016, 64(5):1577-1586. doi: 10.1002/hep.28785 pmid: 27543837
[4]	Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8):1038-1048. doi: 10.1016/j.metabol.2015.12.012
[5]	Weintraub JA, Lopez Mitnik G, Dye BA. Oral diseases associated with nonalcoholic fatty liver disease in the United States[J]. J Dent Res, 2019, 98(11):1219-1226. doi: 10.1177/0022034519866442 pmid: 31369716
[6]	Akinkugbe AA, Slade GD, Barritt AS, et al. Periodontitis and non-alcoholic fatty liver disease, a population-based cohort investigation in the study of health in pomerania[J]. J Clin Periodontol, 2017, 44(11):1077-1087. doi: 10.1111/jcpe.12800 pmid: 28804947
[7]	Kwon T, Lamster IB, Levin L. Current concepts in the manage-ment of periodontitis[J]. Int Dent J, 2021, 71(6):462-476. doi: 10.1111/idj.12630
[8]	Kim S, Bando Y, Chang C, et al. Topical application of Porphyromonas gingivalis into the gingival pocket in mice leads to chronic-active infection, periodontitis and systemic inflammation[J]. Int J Mol Med, 2022, 50(2):103. doi: 10.3892/ijmm
[9]	Ryder MI. Porphyromonas gingivalis and Alzheimer disease:Recent findings and potential therapies[J]. J Periodontol, 2020, 91(Suppl 1):S45-S49.
[10]	Xie MR, Tang QM, Nie JM, et al. BMAL1-downregulation aggravates Porphyromonas gingivalis-induced atherosclerosis by encouraging oxidative stress[J]. Circ Res, 2020, 126(6):e15-e29.
[11]	Kajiwara K, Sawa Y. Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model[J]. BMC Nephrol, 2021, 22(1):287. doi: 10.1186/s12882-021-02506-8
[12]	Omura Y, Kitamoto M, Hyogo H, et al. Morbidly obese patient with non-alcoholic steatohepatitis-related cirrhosis who died from Sepsis caused by dental infection of Porphyromonas gingivalis: A case report[J]. Hepatol Res, 2016, 46(3):E210-E215.
[13]	Alakhali MS, Al-Maweri SA, Al-Shamiri HM, et al. The potential association between periodontitis and non-alcoholic fatty liver disease:A systematic review[J]. Clin Oral Investig, 2018, 22(9):2965-2974. doi: 10.1007/s00784-018-2726-1
[14]	Komazaki R, Katagiri S, Takahashi H, et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism[J]. Sci Rep, 2017, 7(1):13950. doi: 10.1038/s41598-017-14260-9 pmid: 29066788
[15]	Schenkein HA, Loos BG. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases[J]. J Periodontol, 2013, 84(4 Suppl):S51-S69.
[16]	Fujita M, Kuraji R, Ito H, et al. Histological effects and pharmacokinetics of lipopolysaccharide derived from Porphyromonas gingivalis on rat maxilla and liver concerning with progression into non-alcoholic steatohepatitis[J]. J Periodontol, 2018, 89(9):1101-1111. doi: 10.1002/jper.2018.89.issue-9
[17]	Nagasaki A, Sakamoto S, Chea C, et al. Odontogenic infection by Porphyromonas gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation[J]. Sci Rep, 2020, 10:4134. doi: 10.1038/s41598-020-60904-8
[18]	Furusho H, Miyauchi M, Hyogo H, et al. Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice[J]. J Gastroenterol, 2013, 48(11):1259-1270. doi: 10.1007/s00535-012-0738-1 pmid: 23307045
[19]	Varela-López A, Bullón P, Ramírez-Tortosa CL, et al. A diet rich in saturated fat and cholesterol aggravates the effect of bacterial lipopolysaccharide on alveolar bone loss in a rabbit model of periodontal disease[J]. Nutrients, 2020, 12(5):1405. doi: 10.3390/nu12051405
[20]	Sasaki N, Katagiri S, Komazaki R, et al. Endotoxemia by Porphyromonas gingivalis injection aggravates non-alcoholic fatty liver disease, disrupts glucose/lipid metabolism, and alters gut microbiota in mice[J]. Front Microbiol, 2018, 9:2470. doi: 10.3389/fmicb.2018.02470 pmid: 30405551
[21]	Ding LY, Liang LZ, Zhao YX, et al. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-κB and JNK signaling pathways[J]. Oral Dis, 2019, 25(7):1789-1797. doi: 10.1111/odi.v25.7
[22]	Nakahara T, Hyogo H, Ono A, et al. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease[J]. J Gastroenterol, 2018, 53(2):269-280. doi: 10.1007/s00535-017-1368-4 pmid: 28741270
[23]	Wada K, Kamisaki Y. Roles of oral bacteria in cardiovascular diseases:From molecular mechanisms to clinical cases:Involvement of Porphyromonas gingivalis in the development of human aortic aneurysm[J]. J Pharmacol Sci, 2010, 113(2):115-119. doi: 10.1254/jphs.09R22FM
[24]	Tian J, Liu C, Zheng X, et al. Porphyromonas gingivalis induces insulin resistance by increasing BCAA levels in mice[J]. J Dent Res, 2020, 99(7):839-846. doi: 10.1177/0022034520911037 pmid: 32176550
[25]	Wu L, Shi R, Bai HM, et al. Porphyromonas gingivalis induces increases in branched-chain amino acid levels and exacerbates liver injury through livh/livk[J]. Front Cell Infect Microbiol, 2022, 12:776996. doi: 10.3389/fcimb.2022.776996
[26]	Nagasaki A, Sakamoto S, Arai T, et al. Elimination of Porphyromonas gingivalis inhibits liver fibrosis and inflammation in NASH[J]. J Clin Periodontol, 2021, 48(10):1367-1378. doi: 10.1111/jcpe.v48.10
[27]	Saygun I, Nizam N, Keskiner I, et al. Salivary infectious agents and periodontal disease status[J]. J Periodontal Res, 2011, 46(2):235-239. doi: 10.1111/j.1600-0765.2010.01335.x pmid: 21261620
[28]	Yoneda M, Naka SH, Nakano K, et al. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease[J]. BMC Gastroenterol, 2012, 12:16. doi: 10.1186/1471-230X-12-16
[29]	Arimatsu K, Yamada H, Miyazawa H, et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota[J]. Sci Rep, 2014, 4:4828. doi: 10.1038/srep04828 pmid: 24797416
[30]	Nakajima M, Arimatsu K, Kato T, et al. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver[J]. PLoS One, 2015, 10(7):e0134234. doi: 10.1371/journal.pone.0134234
[31]	Yamazaki K, Kato T, Tsuboi Y, et al. Oral pathobiont-induced changes in gut microbiota aggravate the pathology of nonalcoholic fatty liver disease in mice[J]. Front Immunol, 2021, 12:766170. doi: 10.3389/fimmu.2021.766170
[32]	Membrez M, Blancher F, Jaquet M, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice[J]. FASEB J, 2008, 22(7):2416-2426. doi: 10.1096/fj.07-102723 pmid: 18326786
[33]	Vallianou N, Christodoulatos GS, Karampela I, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease:Current evidence and perspectives[J]. Biomolecules, 2021, 12(1):56. doi: 10.3390/biom12010056
[34]	Kato T, Yamazaki K, Nakajima M, et al. Oral administration of Porphyromonas gingivalis alters the gut microbiome and serum metabolome[J]. mSphere, 2018, 3(5):e00460-e00418.
[35]	Zhang ST, Li X, Luo HH, et al. Role of aromatic amino acids in pathogeneses of diabetic nephropathy in Chinese patients with type 2 diabetes[J]. J Diabetes Complications, 2020, 34(10):107667. doi: 10.1016/j.jdiacomp.2020.107667
[36]	Liu RX, Hong J, Xu XQ, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention[J]. Nat Med, 2017, 23(7):859-868. doi: 10.1038/nm.4358 pmid: 28628112
[37]	Du K, Chitneni SK, Suzuki A, et al. Increased glutaminolysis marks active scarring in nonalcoholic steatohepatitis progression[J]. Cell Mol Gastroenterol Hepatol, 2020, 10(1):1-21. doi: S2352-345X(19)30182-1 pmid: 31881361
[38]	Alshawsh MA, Alsalahi A, Alshehade SA, et al. A comparison of the gene expression profiles of non-alcoholic fatty liver disease between animal models of a high-fat diet and methionine-choline-deficient diet[J]. Molecules, 2022, 27(3):858. doi: 10.3390/molecules27030858
[39]	Kini V, Mohanty I, Telang G, et al. Immunopathogenesis and distinct role of Th17 in periodontitis:A review[J]. J Oral Biosci, 2022, 64(2):193-201. doi: 10.1016/j.job.2022.04.005
[40]	Wang LY, Wang JY, Jin Y, et al. Oral administration of all-trans retinoic acid suppresses experimental periodontitis by modulating the Th17/Treg imbalance[J]. J Periodontol, 2014, 85(5):740-750. doi: 10.1902/jop.2013.130132 pmid: 23952076
[41]	Kitamoto S, Nagao-Kitamoto H, Jiao YZ, et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis[J]. Cell, 2020, 182(2):447-462.e14. doi: S0092-8674(20)30681-4 pmid: 32758418
[42]	Hatasa M, Yoshida S, Takahashi H, et al. Relationship between NAFLD and periodontal disease from the view of clinical and basic research, and immunological response[J]. Int J Mol Sci, 2021, 22(7):3728. doi: 10.3390/ijms22073728
[43]	Tomofuji T, Ekuni D, Sanbe T, et al. Effects of improvement in periodontal inflammation by toothbrushing on serum lipopolysaccharide concentration and liver injury in rats[J]. Acta Odontol Scand, 2009, 67(4):200-205. doi: 10.1080/00016350902794818 pmid: 19301160